**Core Concept**
Pre-erythrocytic stage refers to the initial stage of malaria parasite development in the human body, primarily occurring in the liver cells (hepatocytes). Targeting this stage is crucial for preventing the development of the parasite into the erythrocytic stage, which causes the clinical symptoms of malaria.

**Why the Correct Answer is Right**
A drug active against the pre-erythrocytic stage of the malarial parasite would act by inhibiting the replication of the parasite in the liver. This would prevent the parasite from invading red blood cells, thereby reducing the risk of malaria infection. The primary target for such drugs would be the liver cells, where the parasite undergoes asexual reproduction before entering the erythrocytic stage.

**Why Each Wrong Option is Incorrect**

**Option A:** This option is not correct because drugs targeting the pre-erythrocytic stage do not directly affect the parasite in the erythrocytes. Instead, they prevent the parasite from entering the erythrocytic stage in the first place.

**Option B:** This option is incorrect because the pre-erythrocytic stage occurs in the liver cells, not in the blood or tissues outside the liver.

**Option C:** This option is not correct because the pre-erythrocytic stage is a specific stage of the malaria parasite's life cycle, and drugs targeting this stage do not broadly affect the entire parasite lifecycle.

**Clinical Pearl / High-Yield Fact**
A notable example of a drug targeting the pre-erythrocytic stage of the malaria parasite is primaquine. It is used in combination with other antimalarial drugs to prevent the relapse of malaria, particularly in areas where the parasite is resistant to other treatments.

**Correct Answer:** C.